Advertisement

AAPS PharmSciTech

, 20:139 | Cite as

Formulation of Cinnarizine for Stabilization of Its Physiologically Generated Supersaturation

  • Maryam MaghsoodiEmail author
  • Ali Nokhodchi
  • Mahzad Azhdarzadeh Oskuei
  • Saman Heidari
Research Article
  • 34 Downloads

Abstract

Physiologically generated supersaturation and subsequent crystallization of a weakly basic drug in the small intestine leads to compromised bioavailability. In this study, the pH-induced crystallization of cinnarizine (CNZ) in the presence of different polymers was investigated. Inhibitory effect of Eudragit L100 (Eu) on crystallization of CNZ at varying supersaturation ratios was examined. The effect of Eu on the dissolution behavior of CNZ from CNZ/Eu physical mixtures (PMs) and solid dispersions (SDs) was assessed. Results showed that both Eu and hydroxypropyl methylcellulose (HPMC) have a considerable maintenance effect on supersaturation of CNZ but Eu was more effective than HPMC. When Eudragit was used the phenomenon of liquid-liquid phase separation (formation of colloidal phase) was observed at supersaturation ratio of 20 times above the solubility of the drug. PMs showed a higher area under the dissolution curve (AUDC) compared with plain CNZ. In contrast, SDs showed a lower AUDC than plain CNZ. For SDs, the AUDC was limited by the slow release of the drug from Eu in acidic pH which in turn hindered the creation of CNZ supersaturation following the transition of acidic to neutral pH. From these findings, it can be concluded that the ability of the formulation to generate supersaturation state and also maintain the supersaturation is vital for improving the dissolution of CNZ.

KEY WORDS

supersaturation cinnarizine eudragit L100 hydroxypropyl methylcellulose crystallization inhibition dissolution 

Notes

Funding Information

The financial support from Drug Applied Research Center of Tabriz.

University of Medical Sciences is greatly acknowledged.

Compliance with Ethical Standards

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Stahl HP, Nakano M. Pharmaceutical aspects of the drug salt form. In: Stahl PH, Wermuth CG, editors. Handbook of pharmaceutical salts: properties, selection, and use, 1st ed., Zurich. Switzerland: VHCA: Verlag Helvetica Chimica Acta; Weinheim, Federal Republic of Germany: Wiley-VCH; 2002. p. 83–116.Google Scholar
  2. 2.
    Zhou R, Moench P, Heran C, Lu X, Mathias N, Faria TN, et al. pH-dependent dissolution in vitro and absorption in vivo of weakly basic drugs: development of a canine model. Pharm Res. 2005;22:188–92.  https://doi.org/10.1007/s11095-004-1185-3.CrossRefPubMedGoogle Scholar
  3. 3.
    Hsieh YL, Ilevbare GA, Van Eerdenbrugh B, Box KJ, Sanchez-Felix MV, Taylor LS. pH-induced crystallization behavior of weakly basic compounds: determination of extent and duration of supersaturation using potentiometric titration and correlation to solid state properties. Pharm Res. 2012;29:2738–53.  https://doi.org/10.1007/s11095-012-0759-8.CrossRefPubMedGoogle Scholar
  4. 4.
    Kostewicz ES, Wunderlich M, Brauns U, Becker R, Bock T, Dressman JB. Predicting the crystallization of poorly soluble weak bases upon entry in the small intestine. J Pharm Pharmacol. 2004;56:43–51.  https://doi.org/10.1211/0022357022511.CrossRefPubMedGoogle Scholar
  5. 5.
    Brouwers J, Brewster ME, Augustijns P. Supersaturating drug delivery systems: the answer to solubility-limited oral bioavailability? J Pharm Sci. 2009;98:2549–72.  https://doi.org/10.1002/jps.21650.CrossRefPubMedGoogle Scholar
  6. 6.
    Stillhart C, Kuentz M. Trends in the assessment of drug supersaturation and crystallization in vitro using lipid-based delivery systems. J Pharm Sci. 2016;105:2468–76.  https://doi.org/10.1016/j.xphs.2016.01.010.CrossRefPubMedGoogle Scholar
  7. 7.
    Brouwers J, Tack J, Augustijns P. In vitro behavior of a phosphate ester prodrug of amprenavir in human intestinal fluids and in the Caco-2 system: illustration of intraluminal supersaturation. Int J Pharm. 2007;336:302–9.  https://doi.org/10.1016/j.ijpharm.2006.12.011.CrossRefPubMedGoogle Scholar
  8. 8.
    Mellaerts R, Mols R, Kayaert P, Annaert P, Van Humbeeck J, Van den Mooter G, et al. Ordered mesoporous silica induces pH-independent supersaturation of the basic low solubility compound itraconazole resulting in enhanced transepithelial transport. Int J Pharm. 2008;357:169–79.  https://doi.org/10.1016/j.ijpharm.2008.01.049.CrossRefPubMedGoogle Scholar
  9. 9.
    Miller JM, Beig A, Carr RA, Spence JK, Dahan A. A win-win solution in oral delivery of lipophilic drugs: supersaturation via amorphous solid dispersions increases apparent solubility without sacrifice of intestinal membrane permeability. Mol Pharm. 2012;9:2009–16.  https://doi.org/10.1021/mp300104s.CrossRefPubMedGoogle Scholar
  10. 10.
    Takano R, Takata N, Saito R, Furumoto K, Higo S, Hayashi Y, et al. Quantitative analysis of the effect of supersaturation on in vivo drug absorption. Mol Pharm. 2010;7:1431–40.  https://doi.org/10.1021/mp100109a.CrossRefPubMedGoogle Scholar
  11. 11.
    Dahan A, Miller JM. The solubility-permeability interplay and its implications in formulation design and development for poorly soluble drugs. AAPS J. 2012;14:244–51.  https://doi.org/10.1208/s12248-012-9337-6.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Dahan A, Miller JM, Hoffman A, Amidon GE, Amidon GL. The solubility−permeability interplay in using cyclodextrins as pharmaceutical solubilizers: mechanistic modeling and application to progesterone. J Pharm Sci. 2010;99:2739–49.  https://doi.org/10.1002/jps.22033.CrossRefPubMedGoogle Scholar
  13. 13.
    Miller JM, Beig A, Krieg BJ, Carr RA, Borchardt TB, Amidon GE, et al. The solubility−permeability interplay: mechanistic modeling and predictive application of the impact of micellar solubilization on intestinal permeation. Mol Pharm. 2011;8:1848–56.  https://doi.org/10.1021/mp200181v.CrossRefPubMedGoogle Scholar
  14. 14.
    Vandecruys R, Peeters J, Verreck G, Brewster ME. Use of a screening method to determine excipients which optimize the extent and stability of supersaturated drug solutions and application of this system to solid formulation design. Int J Pharm. 2007;342:168–75.  https://doi.org/10.1016/j.ijpharm.2007.05.006.CrossRefPubMedGoogle Scholar
  15. 15.
    Brewster ME, Vandecruys R, Verreck G, Peeters J. Supersaturating drug delivery systems: effect of hydrophilic cyclodextrins and other excipients on the formation and stabilization of supersaturated drug solutions. Pharmazie. 2008;63:217–20.  https://doi.org/10.1691/ph.2008.7326.
  16. 16.
    Curatolo W, Nightingale JA, Herbig SM. Utility of hydroxypropylmethylcellulose acetate succinate (HPMCAS) for initiation and maintenance of drug supersaturation in the GI milieu. Pharm Res. 2009;26:1419–31.  https://doi.org/10.1007/s11095-009-9852-z.CrossRefPubMedGoogle Scholar
  17. 17.
    Raghavan SL, Trividic A, Davis AF, Hadgraft J. Crystallization of hydrocortisone acetate: influence of polymers. Int J Pharm. 2001;212:213–21.  https://doi.org/10.1016/S0378-5173(00)00610-4.CrossRefPubMedGoogle Scholar
  18. 18.
    Miller DA, DiNunzio JC, Yang W, McGinity JW, Williams RO 3rd. Enhanced in vivo absorption of itraconazole via stabilization of supersaturation following acidic-to-neutral pH transition. Drug Dev Ind Pharm. 2008;34:890–902.  https://doi.org/10.1080/03639040801929273.CrossRefPubMedGoogle Scholar
  19. 19.
    Gao P, Akrami A, Alvarez F, Hu J, Li L, Ma C, et al. Characterization and optimization of AMG 517 supersaturatable self-emulsifying drug delivery system (S-SEDDS) for improved oral absorption. J Pharm Sci. 2009;98:516–28.  https://doi.org/10.1002/jps.21451.CrossRefPubMedGoogle Scholar
  20. 20.
    Alhnan MA, Cosi D, Murdan S, Basit AW. Inhibiting the gastric burst release of drugs from enteric microparticles: the influence of drug molecular mass and solubility. J Pharm Sci. 2010;99:4576–83.  https://doi.org/10.1002/jps.22174. CrossRefPubMedGoogle Scholar
  21. 21.
    Gu CH, Rao D, Gandhi RB, Hilden J, Raghavan K. Using a novel multicompartment dissolution system to predict the effect of gastric pH on the oral absorption of weak bases with poor intrinsic solubility. J Pharm Sci. 2005;94:199–208.  https://doi.org/10.1002/jps.20242. CrossRefPubMedGoogle Scholar
  22. 22.
    Järvinen T, Järvinen K, Schwarting N, Stella VJ. Beta-cyclodextrin derivatives, SBE4-beta-CD and HP-beta-CD, increase the oral bioavailability of cinnarizine in beagle dogs. J Pharm Sci. 1995;84:295–9.  https://doi.org/10.1002/jps.2600840306. CrossRefPubMedGoogle Scholar
  23. 23.
    Warren DB, Benameur H, Porter CJ, Pouton CW. Using polymeric crystallization inhibitors to improve the absorption of poorly water-soluble drugs: a mechanistic basis for utility. J Drug Target. 2010;18:704–31.  https://doi.org/10.3109/1061186X.2010.525652.CrossRefPubMedGoogle Scholar
  24. 24.
    Abu-Diak OA, Jones DS, Andrews GP. An investigation into the dissolution properties of celecoxib melt extrudates: understanding the role of polymer type and concentration in stabilizing supersaturated drug concentrations. Mol Pharm. 2011;8:1362–71.  https://doi.org/10.1021/mp200157b.CrossRefPubMedGoogle Scholar
  25. 25.
    Konno H, Handa T, Alonzo DE, Taylor LS. Effect of polymer type on the dissolution profile of amorphous solid dispersions containing felodipine. Eur J Pharm Biopharm. 2008;70:493–9.  https://doi.org/10.1016/j.ejpb.2008.05.023.CrossRefPubMedGoogle Scholar
  26. 26.
    Savolainen M, Kogermann K, Heinz A, Aaltonen J, Peltonen L, Strachan C, et al. Better understanding of dissolution behaviour of amorphous drugs by in situ solid-state analysis using Raman spectroscopy. Eur J Pharm Biopharm. 2009;71:71–9.  https://doi.org/10.1016/j.ejpb.2008.06.001.CrossRefPubMedGoogle Scholar
  27. 27.
    Alonzo DE, Zhang GG, Zhou D, Gao Y, Taylor LS. Understanding the behavior of amorphous pharmaceutical systems during dissolution. Pharm Res. 2010;27:608–18.  https://doi.org/10.1007/s11095-009-0021-1.CrossRefPubMedGoogle Scholar
  28. 28.
    Chauhan H, Hui-Gu C, Atef E. Correlating the behavior of polymers in solution as crystallization inhibitor to its amorphous stabilization ability in solid dispersions. J Pharm Sci. 2013;102:1924–35.  https://doi.org/10.1002/jps.23539.CrossRefPubMedGoogle Scholar
  29. 29.
    Yokoi Y, Yonemochi E, Terada K. Effects of sugar ester and hydroxypropyl methylcellulose on the physicochemical stability of amorphous cefditoren pivoxil in aqueous suspension. Int J Pharm. 2005;290:91–9.  https://doi.org/10.1016/j.ijpharm.2004.11.020.CrossRefPubMedGoogle Scholar
  30. 30.
    Zimmermann A, Millqvist-Fureby A, Elema MR, Hansen T, Müllertz A, Hovgaard L. Adsorption of pharmaceutical excipients onto microcrystals of siramesine hydrochloride: effects on physicochemical properties. Eur J Pharm Biopharm. 2009;71:109–16.  https://doi.org/10.1016/j.ejpb.2008.06.014.CrossRefPubMedGoogle Scholar
  31. 31.
    Douroumis D, Fahr A. Stable carbamazepine colloidal systems using the cosolvent technique. Eur J Pharm Sci. 2007;30:367–74.  https://doi.org/10.1016/j.ejps.2006.12.003.CrossRefPubMedGoogle Scholar
  32. 32.
    Ilevbare GA, Liu H, Edgar KJ, Taylor LS. Understanding polymer properties important for crystal growth inhibition-impact of chemically diverse polymers on solution crystal growth of ritonavir. Cryst Growth Des. 2012;12:3133–43.  https://doi.org/10.1021/cg300325p.CrossRefGoogle Scholar
  33. 33.
    Augustijns P, Brewster ME. Supersaturating drug delivery systems: fast is not necessarily good enough. J Pharm Sci. 2012;101:7–9.  https://doi.org/10.1002/jps.22750.CrossRefPubMedGoogle Scholar
  34. 34.
    Ilevbare GA, Taylor LS. Liquid–liquid phase separation in highly supersaturated aqueous solutions of poorly water-soluble drugs: implications for solubility enhancing formulations. Cryst Growth Des. 2013;13:1497–509.  https://doi.org/10.1021/cg301679h.CrossRefGoogle Scholar
  35. 35.
    Brick MC, Palmer HJ, Whitesides TH. Formation of colloidal dispersions of organic materials in aqueous media by solvent shifting. Langmuir. 2003;19:6367–80.  https://doi.org/10.1021/la034173o.CrossRefGoogle Scholar
  36. 36.
    Tung H-H, Paul EL, Midler M, McCauley JA. Critical issues in crystallization practice. In: Crystallization of organic compounds: an industrial perspective. 1st ed. Hoboken: John Wiley & Sons, Inc; 2009. p. 107.CrossRefGoogle Scholar
  37. 37.
    Almeida e Sousa L, Reutzel-Edens SM, Stephenson GA, Taylor LS. Assessment of the amorphous “solubility” of a group of diverse drugs using new experimental and theoretical approaches. Mol Pharm. 2015;12:484–95.  https://doi.org/10.1021/mp500571m.CrossRefPubMedGoogle Scholar
  38. 38.
    Baghel S, Cathcart H, O’Reilly NJ. Understanding the generation and maintenance of supersaturation during the dissolution of amorphous solid dispersions using modulated DSC and 1H NMR. Int J Pharm. 2018;536:414–25.  https://doi.org/10.1016/j.ijpharm.2017.11.056.CrossRefPubMedGoogle Scholar
  39. 39.
    Raina SA, Van Eerdenbrugh B, Alonzo DE, Mo H, Zhang GGZ, Gao Y, et al. Trends in the crystallization and crystallization behavior of supersaturated aqueous solutions of poorly water-soluble drugs assessed using synchrotron radiation. J Pharm Sci. 2015;104:1981–92.  https://doi.org/10.1002/jps.24423.CrossRefPubMedGoogle Scholar
  40. 40.
    Raina SA, Alonzo DE, Zhang GG, Gao Y, Taylor LS. Using environment-sensitive fluorescent probes to characterize liquid-liquid phase separation in supersaturated solutions of poorly water soluble compounds. Pharm Res. 2015;32:3660–73.  https://doi.org/10.1007/s11095-015-1725-z.CrossRefPubMedGoogle Scholar
  41. 41.
    Indulkar AS, Gao Y, Raina SA, Zhang GG, Taylor LS. Exploiting the phenomenon of liquid–liquid phase separation for enhanced and sustained membrane transport of a poorly water-soluble drug. Mol Pharm. 2016;13:2059–69.  https://doi.org/10.1021/acs.molpharmaceut.6b00202.CrossRefPubMedGoogle Scholar
  42. 42.
    Raina SA, Zhang GGZ, Alonzo DE, Wu J, Zhu D, Catron ND, et al. Enhancements and limits in drug membrane transport using supersaturated solutions of poorly water soluble drugs. J Pharm Sci. 2014;103:2736–48.  https://doi.org/10.1002/jps.23826.CrossRefPubMedGoogle Scholar
  43. 43.
    Heigoldt U, Sommer F, Daniels R, Wagner KG. Predicting in vivo absorption behavior of oral modified release dosage forms containing pH-dependent poorly soluble drugs using a novel pH-adjusted biphasic in vitro dissolution test. Eur J Pharm Biopharm. 2010;76:105–11.  https://doi.org/10.1016/j.ejpb.2010.05.006.CrossRefPubMedGoogle Scholar
  44. 44.
    Kalantzi L, Goumas K, Kalioras V, Abrahamsson B, Dressman JB, Reppas C. Characterization of the human upper gastrointestinal contents under conditions simulating bioavailability/bioequivalence studies. Pharm Res. 2006;23:165–76.  https://doi.org/10.1007/s11095-005-8476-1.CrossRefPubMedGoogle Scholar
  45. 45.
    Alhnan MA, Murdan S, Basit AW. Encapsulation of poorly soluble basic drugs into enteric microparticles: a novel approach to enhance their oral bioavailability. Int J Pharm. 2011;416:55–60.  https://doi.org/10.1016/j.ijpharm.2011.05.079.CrossRefPubMedGoogle Scholar
  46. 46.
    Usul F, Maeda K, Kusai A, Nishimura K, Yamamoto K. Inhibitory effect of water soluble polymers on crystallization of RS-8359. Int J Pharm. 1997;154:59–66.  https://doi.org/10.1016/S0378-5173(97)00129-4.CrossRefGoogle Scholar
  47. 47.
    Guzmán HR, Tawa M, Zhang Z, Ratanabanangkoon P, Shaw P, Gardner CR, et al. Combined use of crystalline salt forms and crystallization inhibitors to improve oral absorption of celecoxib from solid oral formulations. J Pharm Sci. 2007;96:2686–702.  https://doi.org/10.1002/jps.20906.CrossRefPubMedGoogle Scholar
  48. 48.
    Albers J, Alles R, Matthée K, Knop K, Nahrup JS, Kleinebudde P. Mechanism of drug release from polymethacrylate-based extrudates and milled strands prepared by hot-melt extrusion. Eur J Pharm Biopharm. 2009;71:387–94.  https://doi.org/10.1016/j.ejpb.2008.10.002.CrossRefPubMedGoogle Scholar
  49. 49.
    Overhoff KA, Moreno A, Miller DA, Johnston KP, Williams RO 3rd. Solid dispersions of itraconazole and enteric polymers made by ultra-rapid freezing. Int J Pharm. 2007;336:122–32.  https://doi.org/10.1016/j.ijpharm.2006.11.043.CrossRefPubMedGoogle Scholar
  50. 50.
    Zecevic DE, Meier R, Daniels R, Wagner KG. Site specific solubility improvement using solid dispersions of HPMC-AS/HPC SSL--mixtures. Eur J Pharm Biopharm. 2014;87:264–70.  https://doi.org/10.1016/j.ejpb.2014.03.018.CrossRefPubMedGoogle Scholar
  51. 51.
    Kojima T, Higashi K, Suzuki T, Tomono K, Moribe K, Yamamoto K. Stabilization of a supersaturated solution of mefenamic acid from a solid dispersion with EUDRAGIT(®) EPO. Pharm Res. 2012;29:2777–91.  https://doi.org/10.1007/s11095-011-0655-7.CrossRefPubMedGoogle Scholar
  52. 52.
    Loftsson T, Fridriksd_ottir F, Gudmund_sdottir TK. The effect of water-soluble polymers on aqueous solubility of drugs. Int J Pharm. 1996;127:293–6.  https://doi.org/10.1016/0378-5173(95)04207-5. CrossRefGoogle Scholar
  53. 53.
    Dereymaker A, Cinghia G, Van den Mooter G. Eudragit® RL as a stabilizer for supersaturation and a substrate for nanocrystal formation. Eur J Pharm Biopharm. 2017;114:250–62.  https://doi.org/10.1016/j.ejpb.2017.02.002.CrossRefPubMedGoogle Scholar
  54. 54.
    Baghel S, Cathcart H, Redington W, O’Reilly NJ. An investigation into the crystallization tendency/kinetics of amorphous active pharmaceutical ingredients: a case study with dipyridamole and cinnarizine. Eur J Pharm Biopharm. 2016;104:59–71.  https://doi.org/10.1016/j.ejpb.2016.04.017.CrossRefPubMedGoogle Scholar
  55. 55.
    Edueng K, Mahlin D, Larsson P, Bergström CAS. Mechanism-based selection of stabilization strategy for amorphous formulations: insights into crystallization pathways. J Control Release. 2017;256:193–202.  https://doi.org/10.1016/j.jconrel.2017.04.015.CrossRefPubMedPubMedCentralGoogle Scholar
  56. 56.
    Aucamp M, Milne M, Liebenberg W. Amorphous Sulfadoxine: a physical stability and crystallization kinetics study. AAPS PharmSciTech. 2016;17:1100–9.  https://doi.org/10.1208/s12249-015-0436-4.CrossRefPubMedGoogle Scholar
  57. 57.
    Mehta M, Kothari K, Ragoonanan V, Suryanarayanan R. Effect of water on molecular mobility and physical stability of amorphous pharmaceuticals. Mol Pharm. 2016;13:1339–46.  https://doi.org/10.1021/acs.molpharmaceut.5b00950.CrossRefPubMedGoogle Scholar
  58. 58.
    Yu X, Kappes SM, Bello-Perez LA, Schmidt SJ. Investigating the moisture sorption behavior of amorphous sucrose using a dynamic humidity generating instrument. J Food Sci. 2008;73:E25–35.  https://doi.org/10.1111/j.1750-3841.2007.00596.x.CrossRefPubMedGoogle Scholar
  59. 59.
    Haress NG. Cinnarizine: comprehensive profile. Profiles Drug Subst Excip Relat Methodol. 2015;40:1–41.  https://doi.org/10.1016/bs.podrm.2015.01.001. CrossRefPubMedGoogle Scholar
  60. 60.
    Cilurzo F, Minghetti P, Selmin F, Casiraghi A, Montanari L. Polymethacrylate salts as new low-swellable mucoadhesive materials. J Control Release. 2003;88:43–53.  https://doi.org/10.1016/S0168-3659(02)00459-5.CrossRefPubMedGoogle Scholar

Copyright information

© American Association of Pharmaceutical Scientists 2019

Authors and Affiliations

  • Maryam Maghsoodi
    • 1
    Email author
  • Ali Nokhodchi
    • 2
  • Mahzad Azhdarzadeh Oskuei
    • 1
  • Saman Heidari
    • 1
  1. 1.Drug Applied Research Center and School of PharmacyTabriz University of Medical SciencesTabrizIran
  2. 2.Department of Life SciencesUniversity of SussexBrightonUK

Personalised recommendations